Alliance for Regenerative Medicine Announces Agenda for Clinical Outlooks for Regenerative Medicine Meeting

– June 6, 2012

WASHINGTON, DC–(Marketwire -06/05/12)- The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine community, today announced the full agenda for the Clinical Outlooks for Regenerative Medicine meeting. The event will take place on June 19, 2012 at The Starr Center, Schepens Eye Research Institute, 185 Cambridge Street, Boston, MA.

As regenerative medicine and cell therapy products advance further in clinical studies toward gaining approval, it is important to understand how these products will be administered and how they will perform clinically. This meeting, which was organized jointly by ARM and the Harvard Stem Cell Institute, will explore the clinical status for certain key disease areas from the perspective of clinicians, patient groups and leading regenerative medicine companies. The full agenda is as follows:

Clinical Outlooks for Regenerative Medicine

8:30 am : Registration & Light Breakfast

9:00 am : Welcome

Global View of Regenerative Medicine in the Clinical Setting

Brock Reeve, Harvard Stem Cell Institute

Gil Van Bokkelen, Ph.D., ARM; Athersys, Inc.

9:15 am : Ophthalmology Panel


Ellen Feigal, M.D., California Institute for Regenerative Medicine


Gary Rabin, Advanced Cell Technology

Jane Sowden, Ph.D., University College London Institute of Child Health

Michael Young, Ph.D., Schepens Eye Research Institute; Harvard Medical School

10:45 am : Metabolic Panel


Peter Lomedico, Ph.D., JDRF


Jason Gaglia, M.D., M.M.Sc., Joslin Diabetes Center; Harvard Medical School

Bernhard Hering, M.D., Schulze Diabetes Institute; University of Minnesota

Allan Robins, Ph.D., ViaCyte

Mark Zimmerman, Ph.D., BetaLogics, a division of Janssen Pharmaceutical Companies of Johnson & Johnson

12:00 pm : Keynote

George Daley, M.D., Ph.D., HHMI/Children’s Hospital Boston, Harvard Medical School, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Stem Cell Institute and Manton Center for Orphan Disease Research

1:30 pm : Neurodegenerative Disease and Spinal Cord Injury Panel


Amy Comstock Rick, J.D., Parkinson’s Action Network


James Berry, M.D., Ph.D., Massachusetts General Hospital; Harvard Medical School

Stephen Huhn, M.D., F.A.C.S., F.A.A.P., StemCells, Inc.

Mark Noble, Ph.D., University of Rochester Medical Center

Edward Wirth, M.D., Ph.D., InVivo Therapeutics

2:45 pm : Cardiovascular Panel


Richard Lee, M.D., Harvard Medical School; Harvard Stem Cell Institute; Brigham and Women’s Hospital


Marc Penn, M.D., Ph.D., F.A.C.C., Summa Cardiovascular Institute; Summa Akron City Hospital; Northeast Ohio Medical University

Jonathan Sackner-Bernstein, M.D., F.A.C.C., NeoStem

Michael Schuster, Mesoblast

4:15 pm : Wound Healing and Tissue Engineering Panel


Skip Irving, Health Advances


Dolores Baksh, Ph.D., Organogenesis

Charles Hart, Ph.D., Advanced BioHealing, a Shire Company

Ira Herman, Ph.D., Tufts University School of Medicine

Robert Kirsner, M.D., Ph.D., University of Miami School of Medicine

To learn more and to register for the conference, please visit Complimentary registration is available for credentialed members of the media and HSCI affiliated clinicians and researchers.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, click here.

About Harvard Stem Cell Institute

The Harvard Stem Cell Institute (HSCI) is a scientific collaborative established to investigate the complex biology and therapeutic potential of stem cells. With over 200 faculty members at Harvard and its 11 affiliated hospitals, HSCI supports cutting-edge science through sponsoring research projects, operating core facilities, managing events and offering training opportunities.


Michelle Linn
Linnden Communications
Phone: 508-362-3087